Sino Biopharmaceutical

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas.

We recently published a list of Top 8 AI News Updates Investors Should Not Miss. In this article, we are going to take a look at where Nano-X Imaging Ltd. (NASDAQ:NNOX) stands against other top AI news updates investors should not miss.

Biotech company Immunai, which developed an AI-based immune system mapping technology for drug development, announces the appointment of Dr. Mikael Dolsten to its board of directors.

A Beijing-based artificial intelligence (AI) solutions provider is preparing to list in Hong Kong and set up its international headquarters in the city, a minister has said, while vowing to attract more creative enterprises that have adopted innovation and technology-based strategies.

Another company involved in using AI to repurpose failed drugs - as well as drugs that have already been approved - is BioXcel Therapeutics. Unlike Ignota, however, the company focuses on compounds that have already demonstrated safety in prior clinical trials, but have been discontinued by their developers for various other reasons.

A Boston drug discovery company that uses AI has hit unicorn valuation. It uses transformer diffusion models, which its CEO says can "understand the concept of time and how you change, from cradle to grave.

Wen Shuhao helped speed up the development of Pfizer's Covid oral drug, Paxlovid. Now the chairman of Xtalpi wants to help make better solar panels and EV batteries.

Tevogen Bio has expanded its partnership with Microsoft, aiming to further its AI-centred collaboration and advance its predictive precision T-cell targeting technology, PredicTcell.